The first 60 days: Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Appendiceal adenocarcinoma is the invasive, gland-forming form of appendix cancer that behaves more like bowel cancer than the jelly-producing low-grade tumours, spreading to lymph nodes and the abdominal lining. It is treated with right hemicolectomy and bowel-cancer chemotherapy, and peritoneal spread with cytoreductive surgery and heated intraperitoneal chemotherapy in fit patients. Below, week by week, is what OnCo's record of Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Peritoneal metastases, resectable.
- SurgeonNamed in the standard of care for: Localised disease, Peritoneal metastases, resectable, Signet ring cell carcinoma with extensive peritoneal disease.
- Medical oncologistNamed in the standard of care for: Localised disease, Peritoneal metastases, resectable, Unresectable or distant metastatic disease, Signet ring cell carcinoma with extensive peritoneal disease.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Peritoneal metastases, resectable.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Right hemicolectomy with lymphadenectomy; adjuvant FOLFOX or CAPOX for node-positive or high-risk stage II disease, extrapolated from colon cancer.
Cytoreductive surgery with HIPEC (mitomycin or oxaliplatin) in fit patients with limited disease and favourable histology, with perioperative systemic chemotherapy.
FOLFOX or CAPOX with or without bevacizumab; FOLFIRI in second line; pembrolizumab for mismatch-repair-deficient tumours.
- 4.Signet ring cell carcinoma with extensive peritoneal diseaseNCCN Guidelines: Colon Cancer (appendiceal section)
Systemic chemotherapy first; cytoreduction only for exceptional responders.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Histological subtype and grade, TNM stage after right hemicolectomy, Peritoneal cancer index and completeness of cytoreduction, KRAS, GNAS, TP53 and SMAD4 mutations, Mismatch repair and microsatellite status), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Mucinous appendiceal adenocarcinoma, Non-mucinousappendiceal adenocarcinoma, Signet ring cell carcinoma of the appendix.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised disease
- For my situation (localised disease), which of the standard options do you recommend and why?Guideline options include: Right hemicolectomy with lymphadenectomy; adjuvant FOLFOX or CAPOX for node-positive or high-risk stage II disease, extrapolated from colon cancer.
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Peritoneal metastases, resectable
- For my situation (peritoneal metastases, resectable), which of the standard options do you recommend and why?Guideline options include: Cytoreductive surgery with HIPEC (mitomycin or oxaliplatin) in fit patients with limited disease and favourable histology, with perioperative systemic chemotherapy.
- Am I a candidate for Mitomycin C, FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Unresectable or distant metastatic disease
- For my situation (unresectable or distant metastatic disease), which of the standard options do you recommend and why?Guideline options include: FOLFOX or CAPOX with or without bevacizumab; FOLFIRI in second line; pembrolizumab for mismatch-repair-deficient tumours.
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), Bevacizumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Signet ring cell carcinoma with extensive peritoneal disease
- For my situation (signet ring cell carcinoma with extensive peritoneal disease), which of the standard options do you recommend and why?Guideline options include: Systemic chemotherapy first; cytoreduction only for exceptional responders.
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of FOLFOX (5-FU, leucovorin, oxaliplatin), HIPEC / PIPAC (intraperitoneal chemotherapy), Pembrolizumab?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No adjuvant chemotherapy trial has ever been run in appendiceal adenocarcinoma”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Which patients with peritoneal disease benefit from HIPEC is defined only by retrospective series”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell): the full pageAppendiceal adenocarcinoma is the invasive, gland-forming form of appendix cancer that behaves more like bowel cancer than the jelly-producing low-grade tumours, spreading to lymph nodes and the abdominal lining. It is treated with right hemicolectomy and bowel-cancer chemotherapy, and peritoneal spread with cytoreductive surgery and heated intraperitoneal chemotherapy in fit patients.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- HIPEC (hyperthermic intraperitoneal chemotherapy): After surgeons remove all visible tumour from the abdominal lining, the abdomen is bathed for 60-90 minutes in heated chemotherapy to kill the microscopic cells left behind.
- Colectomy: Removing the part of the colon containing the cancer along with its blood supply and lymph nodes, then joining the ends.
- Peritoneal metastasis: Spread across the lining of the abdomen, the most common way stomach cancer recurs and the hardest to treat.
- Lymphadenectomy (lymph node dissection): Surgically removing the lymph nodes that drain a tumour, both to stage the cancer and to clear any spread.
- Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR): Microsatellite instability is the mark of a broken DNA spell-checker (loss of MLH1, MSH2, MSH6 or PMS2) that leaves thousands of mutations, so the tumour displays abnormal proteins that T cells can recognise.
Every term links to the glossary.